Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria

NCT05405660 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT05405660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2022
Completion date
September 12, 2025
Enrollment
196 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inducible urticaria